CA
NZ
UK
AU
IND
US
• 93% Gain Over Three Months: PDF Solutions shares have climbed roughly 93% over the past three months alone, reflecting accelerating momentum.
• $929 Million All-Cash Acquisition: The deal adds YUPELRI, the only approved nebulized LAMA for COPD, with approximately $60 million in annualized cash flow.
• Pivotal Phase 3 AURORA Trial Initiated: The global trial evaluates lead candidate CAN-2409 in advanced non-small cell lung cancer patients who failed prior treatment.
• Phase 3 Enrollment Completed Early: Global enrollment in the 4FRONT-2 trial for wet AMD completed roughly four months ahead of schedule with over 500 patients.
• Barclays Upgrade to Overweight: Barclays lifted the stock to Overweight from Equal-Weight, raising its price target sharply to $414 from $317.
• Russell Growth Index Reclassification: ACM Research was reclassified into the Russell 2000 Growth and Russell 2500 Growth benchmarks, signaling a shift from value to growth.
• Nasdaq-100 Index Addition: Astera Labs joined the Nasdaq-100 Index on June 22, triggering passive fund buying from index-tracking funds.
• Multiple Analyst Price Target Hikes: Bank of America raised its target to $317 and Cantor Fitzgerald to $325, reflecting growing analyst conviction.
• Best Performing S&P 500 Stock in 2026: SanDisk shares are up over 767% year-to-date, cementing its status as the S&P 500's top performer this year.
• Russell 1000 Index Promotion: Nextpower's graduation from the small-cap Russell 2000 to the Russell 1000 and Russell Midcap Value benchmarks signals growing institutional recognition.
Please wait processing your request...